{
    "ticker": "VAXX",
    "name": "Vaxart, Inc.",
    "description": "Vaxart, Inc. is a biotechnology company focused on developing oral vaccines based on its proprietary VAAST (Vaxart's Oral Vaccine Platform) technology. Founded in 2007 and headquartered in South San Francisco, California, Vaxart aims to revolutionize the vaccine industry by offering a convenient and effective alternative to traditional injectable vaccines. The company\u2019s leading product candidates include an oral vaccine for Norovirus, which is a significant cause of gastroenteritis worldwide. Vaxart\u2019s innovative approach offers the potential for easier administration and improved patient compliance, particularly in pediatric and elderly populations. The company is also exploring vaccines for other infectious diseases, including influenza and COVID-19, leveraging its platform to create robust immune responses through oral delivery. Vaxart is at the forefront of vaccine research, with its oral vaccines designed to stimulate mucosal immunity, which is vital for protecting against pathogens at their entry points. The company\u2019s vision is to enhance global health by providing accessible and effective vaccines that can be administered without needles, reducing the burden on healthcare systems and improving vaccination rates.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2007",
    "website": "https://www.vaxart.com",
    "ceo": "Andrei Floroiu",
    "social_media": {
        "twitter": "https://twitter.com/VaxartInc",
        "linkedin": "https://www.linkedin.com/company/vaxart/"
    },
    "investor_relations": "https://ir.vaxart.com",
    "key_executives": [
        {
            "name": "Andrei Floroiu",
            "position": "CEO"
        },
        {
            "name": "James C. M. E. C. Chappell",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Vaccines",
            "products": [
                "Oral Norovirus Vaccine",
                "Oral Influenza Vaccine",
                "Oral COVID-19 Vaccine"
            ]
        }
    ],
    "seo": {
        "meta_title": "Vaxart, Inc. | Innovative Oral Vaccines for Global Health",
        "meta_description": "Explore Vaxart, Inc., a biotechnology company developing oral vaccines using innovative technology. Learn about their mission and product pipeline.",
        "keywords": [
            "Vaxart",
            "Oral Vaccines",
            "Biotechnology",
            "Norovirus",
            "Influenza",
            "COVID-19"
        ]
    },
    "faq": [
        {
            "question": "What is Vaxart known for?",
            "answer": "Vaxart is known for developing oral vaccines using its proprietary VAAST technology."
        },
        {
            "question": "Who is the CEO of Vaxart?",
            "answer": "Andrei Floroiu is the CEO of Vaxart, Inc."
        },
        {
            "question": "Where is Vaxart headquartered?",
            "answer": "Vaxart is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What are Vaxart's main products?",
            "answer": "Vaxart's main products include oral vaccines for Norovirus, Influenza, and COVID-19."
        },
        {
            "question": "When was Vaxart founded?",
            "answer": "Vaxart was founded in 2007."
        }
    ],
    "competitors": [
        "NVAX",
        "MRNA",
        "BNTX",
        "PFE"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}